FDA issues pioglitazone warning based on 5-year study results

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1357, 2011-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone: Results from a 3-Year, Randomized, Comparator-Controlled Study in the US

By Tolman Keith G.  

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 787-800

Adis International

Access to resources Recommend Favorite

Tiratricol warning issued by US FDA

By  

Inpharma, Vol. 1, Iss. 1266, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

US FDA to review bladder cancer risks for pioglitazone

By  

Reactions Weekly, Vol. 1, Iss. 1320, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

FDA alerts to safety issues with gadolinium-based contrast agents

By  

Reactions Weekly, Vol. 1, Iss. 1134, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

US FDA orders boxed warning for all glitazones

By  

Reactions Weekly, Vol. 1, Iss. 1165, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite